Inventprise Analysis: $105M Raised
What is Inventprise?
Inventprise develops and manufactures conjugate vaccines using a proprietary Hydrazide-PEG-Hydrazide linker technology. This platform enables longer-lasting vaccines with broader immune coverage. The company focuses on delivering effective vaccines to low and middle-income countries and global populations.
Location
Redmond, United States
Employees
51-200
Founded
2012
Funding Status
Series A
Product Features & Capabilities
- IVT PCV-25 pneumococcal conjugate vaccine
- Proprietary Hydrazide-PEG-Hydrazide linker conjugation platform
- Scalable conjugation technology for broad-spectrum vaccines
Use Cases
Develop pediatric pneumococcal vaccines with enhanced immune response; Create broad-spectrum conjugate vaccines for global health equity; Manufacture vaccines for low and middle-income countries; Advance mRNA vaccine development using Ntensify® technology; Conduct clinical studies on conjugate vaccines for COVID-19
Other Considerations
Announced breakthrough in COVID-19 conjugate vaccine study published in Vaccine Journal; Selected Quantoom Biosciences’ Ntensify® technology for mRNA vaccine development; Recognized by Life Science Washington as a key industry player; Headquartered in Redmond, WA with 51-200 employees; Founded in 2012
See something that needs updating? Suggest edits to this profile.